WO2005000349A3 - Passive immune therapy against malignant melanoma - Google Patents

Passive immune therapy against malignant melanoma Download PDF

Info

Publication number
WO2005000349A3
WO2005000349A3 PCT/EP2004/006519 EP2004006519W WO2005000349A3 WO 2005000349 A3 WO2005000349 A3 WO 2005000349A3 EP 2004006519 W EP2004006519 W EP 2004006519W WO 2005000349 A3 WO2005000349 A3 WO 2005000349A3
Authority
WO
WIPO (PCT)
Prior art keywords
malignant melanoma
therapy against
immune therapy
against malignant
passive immune
Prior art date
Application number
PCT/EP2004/006519
Other languages
German (de)
French (fr)
Other versions
WO2005000349A2 (en
Inventor
Ursula Wiedermann
Soldano Perrone
Hubert Pehamberger
Otto Scheiner
Original Assignee
Biolife Science Forschungs Und
Ursula Wiedermann
Soldano Perrone
Hubert Pehamberger
Otto Scheiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolife Science Forschungs Und, Ursula Wiedermann, Soldano Perrone, Hubert Pehamberger, Otto Scheiner filed Critical Biolife Science Forschungs Und
Priority to CA002530655A priority Critical patent/CA2530655A1/en
Priority to AU2004251010A priority patent/AU2004251010A1/en
Priority to EP04763003A priority patent/EP1638604A2/en
Publication of WO2005000349A2 publication Critical patent/WO2005000349A2/en
Publication of WO2005000349A3 publication Critical patent/WO2005000349A3/en
Priority to IL172751A priority patent/IL172751A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is the use of antibodies for producing an immunizing vaccine against HMW-MAA on melanomas.
PCT/EP2004/006519 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma WO2005000349A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002530655A CA2530655A1 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma
AU2004251010A AU2004251010A1 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma
EP04763003A EP1638604A2 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma
IL172751A IL172751A0 (en) 2003-06-23 2005-12-22 Passive immune therapy against malignant melanoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10328121.5 2003-06-23
DE10328121A DE10328121A1 (en) 2003-06-23 2003-06-23 Passive immunotherapy for malignant melanoma

Publications (2)

Publication Number Publication Date
WO2005000349A2 WO2005000349A2 (en) 2005-01-06
WO2005000349A3 true WO2005000349A3 (en) 2005-05-06

Family

ID=33546608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006519 WO2005000349A2 (en) 2003-06-23 2004-06-17 Passive immune therapy against malignant melanoma

Country Status (6)

Country Link
EP (1) EP1638604A2 (en)
AU (1) AU2004251010A1 (en)
CA (1) CA2530655A1 (en)
DE (1) DE10328121A1 (en)
IL (1) IL172751A0 (en)
WO (1) WO2005000349A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007011407A (en) * 2005-03-25 2007-11-13 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074279A2 (en) * 1981-09-08 1983-03-16 Suntory Limited Selective anti-tumour agents
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
US5558852A (en) * 1993-03-19 1996-09-24 Duke University Methods of treating melanomas and gliomas with monoclonal antibody Me1-14
WO2001014884A1 (en) * 1999-08-24 2001-03-01 Active Biotech Ab Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633492B2 (en) * 1988-05-17 1993-02-04 Soldano Ferrone Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074279A2 (en) * 1981-09-08 1983-03-16 Suntory Limited Selective anti-tumour agents
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
US5558852A (en) * 1993-03-19 1996-09-24 Duke University Methods of treating melanomas and gliomas with monoclonal antibody Me1-14
WO2001014884A1 (en) * 1999-08-24 2001-03-01 Active Biotech Ab Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENDER H ET AL: "Effects of diagnostic application of monoclonal antibody on survival in melanoma patients", HYBRIDOMA, vol. 16, no. 1, 1997, pages 65 - 68, XP009042149, ISSN: 0272-457X *
MITTELMAN A ET AL: "HUMAN HIGH MOLECULAR WEIGHT MELANOMA-ASSOCIATED ANTIGEN (HMW-MAA) MIMICRY BY MOUSE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY MK2-23: INDUCTION OF HUMORAL ANTI-HMW-MAA IMMUNITY AND PROLONGATION OF SURVIVAL IN PATIENTS WITH STAGE IV MELANOMA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 89, 1992, pages 466 - 470, XP000887127, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
IL172751A0 (en) 2006-04-10
CA2530655A1 (en) 2005-01-06
EP1638604A2 (en) 2006-03-29
WO2005000349A2 (en) 2005-01-06
DE10328121A1 (en) 2005-02-03
AU2004251010A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
HK1081438A1 (en) Induction of antigen specific immune tolerance
IL152896A0 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
CY1111622T1 (en) ANTI-CMET HUMANIZED COMPETITORS
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
AU2002328945A1 (en) Methods for improved treatment of cancer with irinotecan based on mrp1
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2003256912A1 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
NO20040516L (en) Combination therapy for the treatment of cancer.
WO2002080648A3 (en) Mucosal boosting following parenteral priming
AU2003258081A8 (en) Cancer vaccines containing epitopes of oncofetal antigen
AU2002349543A1 (en) Tumor antigens
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
PL356770A1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
MXPA03007036A (en) Method of cancer therapy.
WO2005000204A3 (en) Pancreatic cancer treatment
WO2005000349A3 (en) Passive immune therapy against malignant melanoma
AU2003223538A1 (en) Methods for the treatment of cancer
WO2004106379A8 (en) Immunotherapy of rectal cancer
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.
AU2003229346A1 (en) Use of a vaccine for active immunization against cancer
AU2003268180A1 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
AU2002304883A1 (en) Device for the treatment of tumours
EP1454914A4 (en) Tumor antigen
WO2006070432A3 (en) Anti-tumoral immunogenic peptides and vaccine thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2530655

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 172751

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004251010

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004763003

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004251010

Country of ref document: AU

Date of ref document: 20040617

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004251010

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004763003

Country of ref document: EP